BeInCrypto • October 10th 2026, 10:23 PM
A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year
Key Summary
Moderna's stock has skyrocketed 663% in 2026, outperforming the S&P 500, after its cancer vaccine trial showed promising results and COVID vaccine sales rebounded. The company's shares were down nearly 90% from their pandemic peak in mid-August but have since rebounded, with shares closing up 177% on the news of the trial's success. Moderna is now worth over $89.8 billion, with rivals BioNTech and Genentech also testing a cancer vaccine.
Please see our real time news feed on our Home Page
COVID Vaccine Maker Moderna Surges 663% This Year
COVID Vaccine Performance
Moderna's stock has been a standout performer in 2026, with a 663% gain this year. The company's COVID vaccine sales have rebounded, and its shares have risen significantly since mid-August, when the company's stock was down nearly 90% from its pandemic peak.Trial Results and Outlook
The company's cancer vaccine trial has shown promising results, with investors eagerly awaiting the full numbers on October 24 at a major cancer conference in Madrid. Moderna and Merck have said the vaccine worked, but not shown how well it performs in real-world settings.Market Impact
The news of the trial's success has had a significant impact on Moderna's stock price, with shares closing up 177% on the news. The company is now worth over $89.8 billion, and rivals BioNTech and Genentech are testing a cancer vaccine of their own.Expert Analysis
Not all investors are convinced of Moderna's rally, with Martin Shkreli, a former drug company executive, predicting a short-lived bubble. However, Marco Gerlinger, a professor at Barts Cancer Institute, believes the vaccine provides proof of principle that personalised cancer vaccines work.#MRNA#S#COVID19#Vaccine#Biotech#US